Wogonin induces cell cycle arrest and erythroid differentiation in imatinib-resistant K562 cells and primary CML cells

Oncotarget

Volumn 5, Issue 18, 2014, Pages 8188-8201

  Yang, Hao ^a   Hui, Hui ^a   Wang, Qian ^a   Li, Hui ^a   Zhao, Kai ^a   Zhou, Yuxin ^a   Zhu, Yu ^c   Wang, Xiaotang ^b   You, Qidong ^a   Guo, Qing Long ^a   Lu, Na ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b FLORIDA INTERNATIONAL UNIVERSITY   (United States)

^c THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Cell cycle; CML; Differentiation; GATA 1; Wogonin

Indexed keywords

BENZIDINE; CD71 ANTIGEN; GLYCOPHORIN A; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P21; TRANSCRIPTION FACTOR GATA 1; WOGONIN; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; FLAVANONE DERIVATIVE; GATA1 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; NUCLEAR PROTEIN; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; TRANSCRIPTION FACTOR; ZFPM1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG MECHANISM; ENZYME REGULATION; ERYTHROID CELL; FEMALE; G0 PHASE CELL CYCLE CHECKPOINT; G1 PHASE CELL CYCLE CHECKPOINT; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; K562 CELL LINE; K562R CELL LINE; LEUKEMIA CELL LINE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; UPREGULATION; ANIMAL; CELL CYCLE CHECKPOINT; DOSE RESPONSE; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENETIC TRANSFECTION; GENETICS; LEUKEMIA, ERYTHROBLASTIC, ACUTE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; METABOLISM; NONOBESE DIABETIC MOUSE; PATHOLOGY; RNA INTERFERENCE; SCID MOUSE; SIGNAL TRANSDUCTION; TIME; TUMOR CELL CULTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZAMIDES; CELL CYCLE CHECKPOINTS; CELL DIFFERENTIATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; ERYTHROID CELLS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; FLAVANONES; GATA1 TRANSCRIPTION FACTOR; HUMANS; K562 CELLS; LEUKEMIA, ERYTHROBLASTIC, ACUTE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MAP KINASE KINASE KINASES; MICE, INBRED NOD; MICE, SCID; NUCLEAR PROTEINS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSCRIPTION FACTORS; TRANSFECTION; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84907980701     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2340     Document Type: Article

References (49)

1. Lozzio CB and Lozzio BB. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood. 1975; 45(3):321-334.
2. Tsiftsoglou AS, Pappas IS and Vizirianakis IS. Mechanisms involved in the induced differentiation of leukemia cells. Pharmacol Ther. 2003; 100(3):257-290.
3. Melo JV and Barnes DJ. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer. 2007; 7(6):441-453.
4. Melo JV and Barnes DJ. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nature Reviews Cancer. 2007; 7(6):441-453.
5. Wei W, Huang H, Zhao S, Liu W, Liu C-X, Chen L, Li J-M, Wu Y-L and Yan H. Alantolactone induces apoptosis in chronic myelogenous leukemia sensitive or resistant to imatinib through NF-κB inhibition and Bcr/Abl protein deletion. Apoptosis. 2013; 18(9):1060-1070.
6. Weisberg E and Griffin JD. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood. 2000; 95(11):3498-3505.
7. Krystal GW. Mechanisms of resistance to imatinib (STI571) and prospects for combination with conventional chemotherapeutic agents. Drug Resist Updat. 2001; 4(1):16-21.
8. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN and Sawyers CL. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001; 293(5531):876-880.
9. Demidenko ZN, An WG, Lee JT, Romanova LY, McCubrey JA and Blagosklonny MV. Kinase-addiction and bi-phasic sensitivity-resistance of Bcr-Abl-and Raf-1-expressing cells to imatinib and geldanamycin. Cancer Biol Ther. 2005; 4(4):484-490.
10. Pellicano F, Simara P, Sinclair A, Helgason GV, Copland M, Grant S and Holyoake TL. The MEK inhibitor PD184352 enhances BMS-214662-induced apoptosis in CD34+ CML stem/progenitor cells. Leukemia. 2011; 25(7):1159-1167.
11. Pellicano F, Šimara P, Sinclair A, Helgason GV, Copland M, Grant S and Holyoake TL. The MEK inhibitor PD184352 enhances BMS-214662-induced apoptosis in CD34+ CML stem/progenitor cells. Leukemia. 2011; 25(7):1159-1167.
12. Blagosklonny MV, Fojo T, Bhalla KN, Kim JS, Trepel JB, Figg WD, Rivera Y and Neckers LM. The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy. Leukemia. 2001; 15(10):1537-1543.
13. Weiss MJ, Yu C and Orkin SH. Erythroid-cell-specific properties of transcription factor GATA-1 revealed by phenotypic rescue of a gene-targeted cell line. Mol Cell Biol. 1997; 17(3):1642-1651.
14. Crispino JD. GATA1 in normal and malignant hematopoiesis. Semin Cell Dev Biol. 2005; 16(1):137-147.
15. Grass JA, Boyer ME, Pal S, Wu J, Weiss MJ and Bresnick EH. GATA-1-dependent transcriptional repression of GATA-2 via disruption of positive autoregulation and domain-wide chromatin remodeling. Proc Natl Acad Sci U S A. 2003; 100(15):8811-8816.
16. Letting DL, Chen YY, Rakowski C, Reedy S and Blobel GA. Context-dependent regulation of GATA-1 by friend of GATA-1. Proc Natl Acad Sci U S A. 2004; 101(2):476-481.
17. Nakajima H. Role of transcription factors in differentiation and reprogramming of hematopoietic cells. Keio J Med. 2011; 60(2):47-55.
18. Pevny L, Simon MC, Robertson E, Klein WH, Tsai SF, D'Agati V, Orkin SH and Costantini F. Erythroid differentiation in chimaeric mice blocked by a targeted mutation in the gene for transcription factor GATA-1. Nature. 1991; 349(6306):257-260.
19. Fujiwara Y, Browne CP, Cunniff K, Goff SC and Orkin SH. Arrested development of embryonic red cell precursors in mouse embryos lacking transcription factor GATA-1. Proc Natl Acad Sci U S A. 1996; 93(22):12355-12358.
20. Chlon TM, Dore LC and Crispino JD. Cofactor-mediated restriction of GATA-1 chromatin occupancy coordinates lineage-specific gene expression. Mol Cell. 2012; 47(4):608-621.
21. Zhang H-W, Yang Y, Zhang K, Qiang L, Yang L, Yang L, Hu Y, Wang X-T, You Q-D and Guo Q-L. Wogonin induced differentiation and G1 phase arrest of human U-937 leukemia cells via PKCd phosphorylation. European Journal of Pharmacology. 2008; 591(1-3):7-12.
22. Zhang K, Guo Q-L, You Q-D, Yang Y, Zhang H-W, Yang L, Gu H-Y, Qi Q, Tan Z and Wang X. Wogonin induces the granulocytic differentiation of human NB4 promyelocytic leukemia cells and up-regulates phospholipid scramblase 1 gene expression. Cancer Science. 2008; 99(4):689-695.
23. Dan S, Naito M and Tsuruo T. Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR-ABL tyrosine kinase, CGP 57148. Cell Death Differ. 1998; 5(8):710-715.
24. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S and Sawyers CL. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001; 344(14):1031-1037.
25. Miccio A, Wang Y, Hong W, Gregory GD, Wang H, Yu X, Choi JK, Shelat S, Tong W, Poncz M and Blobel GA. NuRD mediates activating and repressive functions of GATA-1 and FOG-1 during blood development. EMBO J. 2010; 29(2):442-456.
26. Orkin SH. GATA-binding transcription factors in hematopoietic cells. Blood. 1992; 80(3):575-581.
27. Cantor AB and Orkin SH. Coregulation of GATA factors by the Friend of GATA (FOG) family of multitype zinc finger proteins. Semin Cell Dev Biol. 2005; 16(1):117-128.
28. Hong W, Nakazawa M, Chen YY, Kori R, Vakoc CR, Rakowski C and Blobel GA. FOG-1 recruits the NuRD repressor complex to mediate transcriptional repression by GATA-1. EMBO J. 2005; 24(13):2367-2378.
29. Papetti M, Wontakal SN, Stopka T and Skoultchi AI. GATA-1 directly regulates p21 gene expression during erythroid differentiation. Cell Cycle. 2010; 9(10):1972-1980.
30. Matushansky I, Radparvar F and Skoultchi AI. Reprogramming leukemic cells to terminal differentiation by inhibiting specific cyclin-dependent kinases in G1. Proc Natl Acad Sci U S A. 2000; 97(26):14317-14322.
31. Evans T, Reitman M and Felsenfeld G. An erythrocyte-specific DNA-binding factor recognizes a regulatory sequence common to all chicken globin genes. Proc Natl Acad Sci U S A. 1988; 85(16):5976-5980.
32. Cheng Y, King DC, Dore LC, Zhang X, Zhou Y, Zhang Y, Dorman C, Abebe D, Kumar SA, Chiaromonte F, Miller W, Green RD, Weiss MJ and Hardison RC. Transcriptional enhancement by GATA1-occupied DNA segments is strongly associated with evolutionary constraint on the binding site motif. Genome Res. 2008; 18(12):1896-1905.
33. Quintas-Cardama A and Cortes J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood. 2009; 113(8):1619-1630.
34. Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer. 2005; 5(3):172-183.
35. Tokunaga M, Ezoe S, Tanaka H, Satoh Y, Fukushima K, Matsui K, Shibata M, Tanimura A, Oritani K, Matsumura I and Kanakura Y. BCR-ABL but not JAK2 V617F inhibits erythropoiesis through the Ras signal by inducing p21CIP1/WAF1. J Biol Chem. 2010; 285(41):31774-31782.
36. Petrie K, Zelent A and Waxman S. Differentiation therapy of acute myeloid leukemia: past, present and future. Curr Opin Hematol. 2009; 16(2):84-91.
37. Bellos F and Mahlknecht U. Valproic acid and all-trans retinoic acid: meta-analysis of a palliative treatment regimen in AML and MDS patients. Onkologie. 2008; 31(11):629-633.
38. Chou ST, Khandros E, Bailey LC, Nichols KE, Vakoc CR, Yao Y, Huang Z, Crispino JD, Hardison RC, Blobel GA and Weiss MJ. Graded repression of PU.1/Sfpi1 gene transcription by GATA factors regulates hematopoietic cell fate. Blood. 2009; 114(5):983-994.
39. Rylski M, Welch JJ, Chen YY, Letting DL, Diehl JA, Chodosh LA, Blobel GA and Weiss MJ. GATA-1-mediated proliferation arrest during erythroid maturation. Mol Cell Biol. 2003; 23(14):5031-5042.
40. Tsiftsoglou AS, Vizirianakis IS and Strouboulis J. Erythropoiesis: model systems, molecular regulators, and developmental programs. IUBMB Life. 2009; 61(8):800-830.
41. Bresnick EH, Katsumura KR, Lee HY, Johnson KD and Perkins AS. Master regulatory GATA transcription factors: mechanistic principles and emerging links to hematologic malignancies. Nucleic Acids Res. 2012; 40(13):5819-5831.
42. Wang H, Zhao L, Zhu LT, Wang Y, Pan D, Yao J, You QD and Guo QL. Wogonin reverses hypoxia resistance of human colon cancer HCT116 cells via downregulation of HIF-1alpha and glycolysis, by inhibiting PI3K/Akt signaling pathway. Mol Carcinog. 2013.
43. Jaaro H RH, Hanoch T, Seger R. Nuclear translocation of mitogen-activated protein kinase kinase (MEK1) in response to mitogenic stimulation. Proc Natl Acad Sci U S A. 1997.
44. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson RA and Kantarjian HM. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010; 362(24):2251-2259.
45. Li Z-Y, Cao X, Wang X, Guo Q-L and You Q-D. Convenient Synthesis of Wogonin, A Flavonoid Natural Product with Extensive Pharmacological Activity. Organic Preparations and Procedures International. 2009; 41(4):327-330.
46. Tian K, Yang S, Ren Q, Han Z, Lu S, Ma F and Zhang L. p38 MAPK contributes to the growth inhibition of leukemic tumor cells mediated by human umbilical cord mesenchymal stem cells. Cell Physiol Biochem. 2010; 26(6):799-808.
47. de Thonel A, Vandekerckhove J, Lanneau D, Selvakumar S, Courtois G, Hazoume A, Brunet M, Maurel S, Hammann A, Ribeil JA, Zermati Y, Gabet AS, Boyes J, Solary E, Hermine O and Garrido C. HSP27 controls GATA-1 protein level during erythroid cell differentiation. Blood. 2010; 116(1):85-96.
48. Chen Y, Hui H, Yang H, Zhao K, Qin Y, Gu C, Wang X, Lu N and Guo Q. Wogonoside induces cell cycle arrest and differentiation by affecting expression and subcellular localization of PLSCR1 in AML cells. Blood. 2013; 121(18):3682-3691.
49. Huang C, Cao J, Huang KJ, Zhang F, Jiang T, Zhu L and Qiu ZJ. Inhibition of STAT3 activity with AG490 decreases the invasion of human pancreatic cancer cells in vitro. Cancer Sci. 2006; 97(12):1417-1423.